You may also like these news :
Drug Company Not Allowed To Hide Behind FDA--Baby Boy's Cancer Linked To Novartis Pharmaceutical's Elidel
US District Court ruling allows parents of cancer victim to proceed in their litigation against Elidel manufacturer Novartis Pharmaceuticals. Novartis' Motion to Dismiss was denied after their argument that FDA labeling regulations prevented their notification of physicians and patients was deemed to be invalid. This landmark decision will have lasting impact on product and drug liability cases throughout the United States where the case relies upon a manufacturer's failure to notify of potential dangers. (PRWeb Oct 27, 2006) Trackback URI: http://www.prweb.com/zingpr.php/RmFsdS1QaWdnLUhvcnItRW1wdC1NYWduLVplcm8=